---
title: "Appyea 2025 10-K: $7.6k Revenue, $(15.10) M Net Loss"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282990342.md"
description: "Appyea reported fiscal 2025 revenue of $7,625 and a net loss of $15.097 million, primarily due to fair value remeasurements of contingent liabilities and convertible loans. Operating expenses totaled $16.929 million, with significant increases in General & Administrative costs. Revenue decreased from $29,000 in 2024 to $7,625 in 2025, indicating limited commercial traction. The company continued R&D on its AppySleep product and completed the acquisition of Techlott technology to enhance its product offerings. Multiple financing efforts were executed to support operations and align management incentives."
datetime: "2026-04-16T11:25:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282990342.md)
  - [en](https://longbridge.com/en/news/282990342.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282990342.md)
generator: "portal-rs"
---

# Appyea 2025 10-K: $7.6k Revenue, $(15.10) M Net Loss

Appyea reported fiscal 2025 revenue of $7,625 and a net loss of $15.097 million, driven principally by fair value remeasurements of contingent liabilities and convertible loans that materially increased operating expenses; earnings per share was not provided. The company’s minimal revenue reflects limited commercial traction for its products while one-time and equity-related adjustments significantly affected the period’s results.

**Financial Highlights**

-   **Revenues**: $0.0076 million (2025: $7,625; 2024: $29,000).
-   **Net Income (Loss)**: $(15.097) million for 2025, primarily due to fair value remeasurement of contingent liabilities and convertible loans.
-   **Operating Expenses**: $16.929 million total for 2025, comprising Research & Development $0.240 million and General & Administrative $16.689 million. The increase in G&A was driven by fair value remeasurement impacts.

**Business Highlights**

-   **Revenue Trend**: Revenue remained minimal at $7.6k in 2025 versus $29k in 2024, indicating limited commercial traction for Appyea’s products.
-   **Product Development**: Continued research and development on the AppySleep wristband and iOS app, with reduced R&D spend focused on completing design and development.
-   **Operational Scale-up**: Recognition of contingent liabilities and equity-related instruments tied to strategic transactions materially increased G&A expense during the period.
-   **Strategic Transactions and Acquisitions**: Completed acquisition of Techlott technology in a transaction settled primarily in stock to expand intellectual property and the product roadmap.
-   **Financing and Incentives**: Executed multiple subscription financings and issued milestone-linked shares and warrants to fund operations and align management incentives with performance milestones.

Original SEC Filing: APPYEA, INC \[ APYP \] - 10-K - Apr. 16, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [APYP.US](https://longbridge.com/en/quote/APYP.US.md)
- [LOTT.US](https://longbridge.com/en/quote/LOTT.US.md)

## Related News & Research

- [AppYea Delays Annual 10-K Filing Briefly](https://longbridge.com/en/news/281286342.md)
- [ZYUS Life Sciences Corporation Announces Completion of Secured Loan Financing](https://longbridge.com/en/news/297568176.md)
- [Londax delays annual 10-K filing as audit takes longer than expected](https://longbridge.com/en/news/297554052.md)
- [Longevity Diversified Holdings delays annual 10-K filing for year ended May 31, 2026](https://longbridge.com/en/news/297554404.md)
- [Ares Capital's Non-Accruals Rose to 2.4% of Its Portfolio, Still Below Its Own Historical Average](https://longbridge.com/en/news/297427279.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**